

6-1-2016

## The risk and nature of flares in juvenile idiopathic arthritis: Results from the ReACCh-Out cohort

Jaime Guzman  
*The University of British Columbia*

Kiem Oen  
*University of Manitoba*

Adam M. Huber  
*Dalhousie University*

Karen Watanabe Duffy  
*Children's Hospital of Eastern Ontario, Ottawa*

Gilles Boire  
*Centre Hospitalier Universitaire de Sherbrooke*

*See next page for additional authors*

Follow this and additional works at: <https://ir.lib.uwo.ca/paedpub>

---

### Citation of this paper:

Guzman, Jaime; Oen, Kiem; Huber, Adam M.; Duffy, Karen Watanabe; Boire, Gilles; Shiff, Natalie; Berard, Roberta A.; Levy, Deborah M.; Stringer, Elizabeth; Scuccimarrì, Rosie; Morishita, Kimberly; Johnson, Nicole; Cabral, David A.; Rosenberg, Alan M.; Larché, Maggie; Dancy, Paul; Petty, Ross E.; Laxer, Ronald M.; Silverman, Earl; Miettunen, Paivi; Chetaille, Anne Laure; Haddad, Elie; Houghton, Kristin; Spiegel, Lynn; Turvey, Stuart E.; Schmeling, Heinrike; Lang, Bianca; Ellsworth, Janet; and Ramsey, Suzanne E., "The risk and nature of flares in juvenile idiopathic arthritis: Results from the ReACCh-Out cohort" (2016). *Paediatrics Publications*. 796.  
<https://ir.lib.uwo.ca/paedpub/796>

---

## Authors

Jaime Guzman, Kiem Oen, Adam M. Huber, Karen Watanabe Duffy, Gilles Boire, Natalie Shiff, Roberta A. Berard, Deborah M. Levy, Elizabeth Stringer, Rosie Scuccimarri, Kimberly Morishita, Nicole Johnson, David A. Cabral, Alan M. Rosenberg, Maggie Larché, Paul Dancey, Ross E. Petty, Ronald M. Laxer, Earl Silverman, Paivi Miettunen, Anne Laure Chetaille, Elie Haddad, Kristin Houghton, Lynn Spiegel, Stuart E. Turvey, Heinrike Schmeling, Bianca Lang, Janet Ellsworth, and Suzanne E. Ramsey



ORAL PRESENTATION

Open Access

# The risk and nature of flares in juvenile idiopathic arthritis: results from the reACCh-Out cohort

Jaime Guzman<sup>1\*</sup>, Kiem Oen<sup>2</sup>, Adam M Huber<sup>3</sup>, Gilles Boire<sup>4</sup>, Karen Watanabe Duffy<sup>5</sup>, Roberta Berard<sup>6</sup>, Natalie J Shiff<sup>7</sup>, Deborah M Levy<sup>8</sup>, Elizabeth Stringer<sup>3</sup>, Kimberly Morishita<sup>1</sup>, Rosie Scuccimarri<sup>9</sup>, Lori B Tucker<sup>1</sup>, Rae SM Yeung<sup>8</sup>, Ciaran Duffy<sup>5</sup>, ReACCh-Out Investigators

From 21st European Pediatric Rheumatology (PReS) Congress  
Belgrade, Serbia. 17-21 September 2014

## Introduction

Accurate description of the risk and nature of flares will help counsel families when JIA is controlled and when considering discontinuing treatment.

## Objectives

To describe the probability and characteristics of flares across JIA categories in an inception cohort of Canadian children treated with a contemporary approach.

## Methods

We studied children diagnosed with JIA between 2005 and 2010 who had at least one visit with inactive disease while being prospectively followed in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) cohort. They received usual pediatric rheumatology care at 16 Canadian centres. Flare was defined as any recurrence of disease manifestations after attaining

inactive disease (no active joints, no extraarticular manifestations and a physician global assessment <10mm). Flares were considered major if they required re-initiation or intensification (a new drug was started) of anti-rheumatic treatment. Risk of flare was calculated with Kaplan-Meier survival methods starting at the time of attainment of inactive disease, and at the time of discontinuing all treatment.

## Results

Of 1492 children recruited in ReACCh-Out, 1128 had at least one visit with inactive disease. Median follow-up was 24 months (IQR 12, 39) after attaining inactive disease. A total of 1,179 flares were observed in 532 patients; 55% of all flares were major flares. The cumulative probability of flare was 25%, 42% and 60% within 6, 12 and 24 months after attaining inactive disease, respectively. By 24 months the risk varied from 49% for systemic JIA to 72% for

**Table 1 Cumulative probability of flare within 6 and 12 months of stopping treatment**

JIA category	Subjects stopping treatment / total	Risk within 6 months (%)		Risk within 12 months (%)	
		Any flare	Major flare	Any flare	Major flare
Systemic arthritis	37 / 66	11	3	11	3
Psoriatic arthritis	44 / 75	12	12	15	15
Oligoarthritis	318 / 481	15	12	32	26
Undifferentiated arthritis	60 / 111	24	13	28	18
Enthesitis-related arthritis	77 / 152	29	21	45	33
RF-negative polyarthritis	85 / 209	25	20	45	40
RF-positive polyarthritis	4 / 34	-	-	-	-

<sup>1</sup>U of British Columbia, Vancouver, Canada

Full list of author information is available at the end of the article

RF-positive polyarthritis. 625 patients discontinued all treatment. The probability of flares after stopping treatment is shown in the Table (except for RF-positive polyarthritis because only 4 subjects discontinued treatment). Table 1

### Conclusion

Flares after attaining inactive disease were common in this JIA cohort, and the risk was lowest for systemic JIA and highest for RF-positive polyarthritis. Flares after stopping treatment were uncommon in systemic JIA, but occurred in up to 45% of children within one year in other JIA categories. About half the flares required intensification or re-initiation of treatment.

### Disclosure of interest

None declared.

### Authors' details

<sup>1</sup>U of British Columbia, Vancouver, Canada. <sup>2</sup>U of Manitoba, Winnipeg, Canada. <sup>3</sup>Dalhousie University, Halifax, Canada. <sup>4</sup>U de Sherbrooke, Sherbrooke, Canada. <sup>5</sup>U of Ottawa, Ottawa, Canada. <sup>6</sup>Western University, London, Canada. <sup>7</sup>U of Saskatchewan, Saskatoon, Canada. <sup>8</sup>U of Toronto, Toronto, Canada. <sup>9</sup>McGill University, Montreal, Canada.

Published: 17 September 2014

doi:10.1186/1546-0096-12-S1-O9

**Cite this article as:** Guzman *et al.*: The risk and nature of flares in juvenile idiopathic arthritis: results from the reACCh-Out cohort. *Pediatric Rheumatology* 2014 **12**(Suppl 1):O9.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

